More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$11.74B
EPS
7.4
P/E ratio
17.1
Price to sales
1.59
Dividend yield
--
Beta
1.269658
Previous close
$163.11
Today's open
$162.62
Day's range
$144.27 - $164.72
52 week range
$125.10 - $211.00
show more
CEO
Barry Balfe
Employees
39800
Headquarters
Dublin 18,
Exchange
Nasdaq Global Select
Shares outstanding
80756860
Issue type
American Depository Receipt
Healthcare
Biotechnology & Life Sciences
ICON's Accellacare Site Network Expands Oncology Research Capabilities With New Cancer Institute Partnership
DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR) today announced a significant expansion of oncology research capabilities within its Accellacare Site Network through the opening of the Brian Moran Cancer Institute at Duly Health and Care in Illinois. The new institute strengthens Accellacare's ability to support oncology clinical trials and broaden access to innovative cancer treatments for patients. The Brian Moran Cancer Institute includes: ‒ 14 medical oncologists ‒ Three radiation oncologi.
Business Wire • Jan 27, 2026

GreensKeeper Value Fund Q4 2025 Portfolio Update: Long-Term Winners
GreensKeeper Value Fund Q4 2025 Portfolio Update: Long-Term Winners
Seeking Alpha • Jan 27, 2026

ICON 2025 global biotech survey solidifies China dominance and highlights opportunities for Western biotechs to stay competitive
DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today released findings from two biotech sector surveys. The first survey focused on global biotech trends and is an update of our 2023 survey, while the second survey focused exclusively on trends in the rapidly growing Chinese biotech market. In total, both surveys captured insights from more than 260 biotech professionals and venture capital executives across the US, Europe, Asia-Pacific (APAC).
Business Wire • Dec 9, 2025

ICON Survey Reveals Increasing Clinical Trial Startup Delays, Underscoring Need for Human-Centred Site Activation Solutions
DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today announced results of its latest industry survey, examining the challenges clinical trial sites face during study startup. The findings underscore the need for a site-centric, collaborative approach to overcome bottlenecks and enhance trial activation timelines. The survey, conducted in June 2025 among just over 100 principal investigators and senior clinical trial site personnel, gathered per.
Business Wire • Dec 2, 2025

ICON Public Limited Company (ICLR) Presents at Jefferies London Healthcare Conference 2025 Transcript
ICON Public Limited Company ( ICLR ) Jefferies London Healthcare Conference 2025 November 19, 2025 4:00 AM EST Company Participants Barry Balfe - CEO & Director Nigel Clerkin - Chief Financial Officer Conference Call Participants David Windley - Jefferies LLC, Research Division Presentation David Windley Jefferies LLC, Research Division All right. Good morning, everybody.
Seeking Alpha • Nov 20, 2025

ICON plc to Present at the Jefferies London Healthcare Conference
DUBLIN--(BUSINESS WIRE)--ICON plc to Present at the Jefferies London Healthcare Conference.
Business Wire • Nov 12, 2025

Invesco International Small-Mid Company Fund Q3 2025 Top Contributors And Detractors
Invesco International Small-Mid Company Fund outperformed most in the real estate and consumer staples sectors due to stock selection. The fund's underweight in real estate also added to relative return. The fund underperformed most in healthcare, information technology and materials due to stock selection.
Seeking Alpha • Nov 5, 2025

ICON Public Limited Company (ICLR) Q3 2025 Earnings Call Transcript
ICON Public Limited Company (NASDAQ:ICLR ) Q3 2025 Earnings Call October 23, 2025 8:00 AM EDT Company Participants Kate Haven - Vice President of Investor Relations Steven Cutler Barry Balfe - CEO & Director Nigel Clerkin - Chief Financial Officer Conference Call Participants Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Michael Cherny - Leerink Partners LLC, Research Division Justin Bowers - Deutsche Bank AG, Research Division Jailendra Singh - Truist Securities, Inc., Research Division Patrick Donnelly - Citigroup Inc., Research Division Jack Meehan - Nephron Research LLC Eric Coldwell - Robert W. Baird & Co. Incorporated, Research Division Charles Rhyee - TD Cowen, Research Division Michael Ryskin - BofA Securities, Research Division David Windley - Jefferies LLC, Research Division Kyle Crews - UBS Investment Bank, Research Division Luke Sergott - Barclays Bank PLC, Research Division Christine Rains - William Blair & Company L.L.C.
Seeking Alpha • Oct 23, 2025

ICON Reports Third Quarter 2025 Results
DUBLIN--(BUSINESS WIRE)--ICON Reports Third Quarter 2025 Results.
Business Wire • Oct 22, 2025

Icon PLC (ICLR) Surpasses Q3 Earnings and Revenue Estimates
Icon PLC (ICLR) came out with quarterly earnings of $3.31 per share, beating the Zacks Consensus Estimate of $3.28 per share. This compares to earnings of $3.35 per share a year ago.
Zacks Investment Research • Oct 22, 2025

¹ Disclosures

Open an M1 investment account to buy and sell ICON plc commission-free¹. Build wealth for the long term using automated trading and transfers.